Upf1069

Manufactured by Selleck Chemicals

Sourced in United States

The UPF1069 is a specialized laboratory equipment designed for conducting various scientific experiments and analyses. It features precise temperature control, advanced data monitoring capabilities, and durable construction to ensure reliable performance in a laboratory setting. The core function of the UPF1069 is to provide a controlled and stable environment for conducting experiments, but its specific intended use is not provided in this description.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using upf1069

Evaluation of Small Molecule Inhibitors

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

BMN673 was obtained from Medivation, a collaborator of NCI. The Parp1/2 inhibitor PJ34 (ref. 29 (link); Calbiochem) was used at 5 μmol/L final concentration. 8-(4-Dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one (NU7441, Tocris), a highly specific DNA-PKcs inhibitor (30 (link)), was used at 5 μmol/L final concentration. Rad51 inhibitor B-02 (ref. 31 (link); Merck-Millipore) was used at 25 μmol/L final concentration. AG14361 (specific Parp1 inhibitor; ref. 32 (link)), olaparib (Parp1/2 inhibitor), ME0328 (Parp3 inhibitor; ref. 33 (link)), and UPF1069 (Parp2 inhibitor; ref. 34 (link)) were purchased from Selleckchem and used at 400 nmol/L (AG14361), 1 μmol/L (UPF1069) or 3 μmol/L (all others).

Soni A., Li F., Wang Y., Grabos M., Krieger L.M., Chaudhary S., Hasan M.S., Ahmed M., Coleman C.N., Teicher B.A., Piekarz R.L., Wang D, & Iliakis G.E. (2018). Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks. Molecular cancer therapeutics, 17(10), 2206-2216.

+ Open protocol

+ Expand

Comprehensive Compound Library for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following compounds were provided by Selleck Chemicals (Houston, TX): 5-fluorouracil (#S1209), adavosertib (#S1525), B02 (#S8434), berzosertib (#S7102), campthotecin (#S1288), cisplatin (#S1166), etoposide (#S1225), gemcitabine (#S1714), GSK'872 (#S8465), hydroxyurea (#S1896), irinotecan (#S2217), KU-55933 (#S1092), KU-60019 (#S1570), mirin (#S8096), nocodazole (#S2775), NU7026 (#S2893), olaparib (#S1060), oxaliplatin (#S1224), prexasertib (#S7178), Q-VD-Oph (#S7311), rabusertib (#S2626), rucaparib (#S1098), talazoparib (#S7048), triapine (#S7470), UPF 1069 (#S8038) VE-821 (#S8007), and veliparib (#S1004). Verapamil (#V4629) were provided by Sigma-Aldrich, CCT241533 (#HY-14715B) by MedChem Express (Monmouth Junction, NJ), NP-004255 (#PC-61922) by ProbeChem (Shanghai, China), and PV1019 (#220488) by Calbiochem-Merck-Millipore (Billerica, MA). The appropriate amount of DMSO (#5879) was employed for negative control conditions.

Manic G., Musella M., Corradi F., Sistigu A., Vitale S., Soliman Abdel Rehim S., Mattiello L., Malacaria E., Galassi C., Signore M., Pallocca M., Scalera S., Goeman F., De Nicola F., Guarracino A., Pennisi R., Antonangeli F., Sperati F., Baiocchi M., Biffoni M., Fanciulli M., Maugeri-Saccà M., Franchitto A., Pichierri P., De Maria R, & Vitale I. (2021). Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death and Differentiation, 28(7), 2060-2082.

+ Open protocol

+ Expand

PARP Inhibitor Compounds Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

The PARP inhibitors used in this study were purchased from Selleckchem (Houston, TX, USA) with the following names and catalog numbers: A-966492 (catalog number S2197), AG14361 (catalog number S2178), AZD2461 (catalog number S7029), E7449 (catalog number S8419), G007-LK (catalog number S7239), Niraparib (MK-4827; catalog number S2741), NMS-P118 (catalog number S8363), NU1025 (catalog number S7730), Olaparib (AZD2281, Ku-0059436; catalog number S1060), PJ34-HCl (catalog number S7300), Rucaparib (AG-014699, PF-01367338; catalog number S1098), Talazoparib (BMN673; catalog number S7048), and UPF1069 (catalog number S8038). Stock solutions were dissolved in dimethyl sulfoxide (DMSO) according to the manufacturer’s protocol to a concentration of 10 mM and stored at −20 °C. Table 1 lists the PARP inhibitors used in this study and their proposed targets.

Keung M.Y., Wu Y., Badar F, & Vadgama J.V. (2020). Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. Journal of Clinical Medicine, 9(4), 940.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!